IP Library Granted Patent US 10,316,034
Granted Patent B2
US 10,316,034 · App. 15/567,536 · Granted Jun 11, 2019

Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO)

Inventors: Edward Savory (Cambridge, GB); Michael Higginbottom (Cambridge, GB)
Assignee: BENEVOLENTAI CAMBRIDGE LIMITED
C07D471/04A61P7/12A61P9/04A61P9/10A61P17/04A61P17/06A61P25/08A61P25/16A61P25/28A61P27/02A61P29/00A61P31/00A61P37/02A61P37/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,316,034
App. No.
15/567,536
Granted
Jun 11, 2019
Kind
B2
Abstract

The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.

Claims (12)

1. A compound selected from:

(3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate having a melting point of 189° C., and

(3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate sulfate 1.5H 2 O having a melting point of 106° C.

2. A pharmaceutical composition comprising:

the compound according to claim 1 , and

one or more suitable excipients.

3. The compound according to claim 1 , which is (3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate having a melting point of 189° C.

4. The compound according to claim 3 having a purity of greater than 99.5%.

5. The compound according to claim 3 having an enantiomeric purity of greater than 99.5%.

6. The compound according to claim 1 , which is (3 S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate sulfate 1.5H 2 O having a melting point of 106° C.

7. The compound according to claim 6 having a purity of greater than 99.3%.

8. The compound according to claim 6 having an enantiomeric purity of greater than 99.3%.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2022
From: BENEVOLENTAI CAMBRIDGE LIMITED
To: PROXIMAGEN, LLC
Reel/Frame 059761/0379 →
CHANGE OF ADDRESS Recorded Mar 22, 2019
From: BENEVOLENTAI CAMBRIDGE LIMITED
To: BENEVOLENTAI CAMBRIDGE LIMITED
Reel/Frame 048676/0176 →
CHANGE OF NAME Recorded Dec 17, 2018
From: PROXIMAGEN LIMITED
To: BENEVOLENTAI CAMBRIDGE LIMITED
Reel/Frame 047799/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2017
From: SAVORY, EDWARD; HIGGINBOTTOM, MICHAEL
To: PROXIMAGEN LIMITED
Reel/Frame 043905/0248 →
Priority Claims (1)
GB 1507031.1 · Apr 24, 2015 · national
Continuity (1)
Related Publication 20180111928A1 · Apr 26, 2018